Drug Profile


Alternative Names: PTT 119

Latest Information Update: 23 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proter
  • Developer Abbott GmbH & Co. KG
  • Class Antineoplastics; Nitrogen mustard compounds
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Small cell lung cancer

Most Recent Events

  • 23 Jan 2013 Discontinued - Phase-II for Small cell lung cancer in Italy (IV)
  • 23 Jan 2013 Discontinued - Preregistration for Non-Hodgkin's lymphoma in Italy (IV)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top